

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No 05-939-A (EX02-125C-US))

In the Application of: )  
Francis-Lang *et al.* )  
Serial No.: 10/523,588 )  
Filing Date: February 4, 2005 )  
For: CSNK1Gs as Modifiers of the p21 )  
Pathway and Methods of Use )  
Examiner: Swope, Sheridan  
Group Art Unit: 1652  
Confirmation No. 4379

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the restriction requirement mailed on October 27, 2006 in the above-mentioned application. Applicant submits herewith a petition for a five month extension of time and the appropriate fee. It is believed that no further fee is due in connection with this filing. However, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

With respect to the restriction requirement, Applicant hereby elects with traverse Group I, claims 16 and 2, 3, 6, and 17, drawn to a method of identifying a candidate p21 pathway modulating agent, for prosecution on the merits. Applicant further elects with traverse a cell proliferation assay. Applicant notes that the restriction requirement states that claim 1 links the inventions of Group I – VII: Group I (claims 16 and 2, 3, 6, and 17), Group II (claims 4 and 5), Group III (claim 7), Group IV (claims 8-10 in part), Group V (claims 8-10 in part), Group VI (claims 11 [in part] and 12), and Group VII (claim 11 [in part]) claims. Upon allowance of the linking claim (claim 1), the restriction requirement as to the linked inventions of Group I - VII claims shall be withdrawn.